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Background: Consensus on the definition of airflow obstruction to diagnose COPD remains 
unresolved.
Methods: We undertook systematic case finding for COPD in primary care using the fixed ratio 
(FR) criterion (forced expiratory volume in 1 s/forced vital capacity [FEV
1
/FVC] 0.7) for 
defining airflow obstruction and also using the lower limit of normal (LLN). We then compared 
the clinical characteristics of those identified by the 2 criteria.
Results: A total of 3,721 individuals reporting respiratory symptoms were invited for spirom-
etry. A total of 2,607 attended (mean age 60.4 years, 52.8% male, 29.8% current smokers) and 
32.6% had airflow obstruction by FR (“FR+”) and 20.2% by LLN (“LLN+”). Compared with 
the LLN+/FR+ group, the LLN−/FR+ group (12.4%) was significantly older, had higher FEV
1
 
and FEV
1
/FVC, lower COPD assessment test scores, and less cough, sputum, and wheeze, 
but was significantly more likely to report a diagnosis of heart disease (14.2% versus 6.9%, 
p0.001). Compared with the LLN+/FR+ group, the LLN−/FR− group was younger, had a 
higher body mass index, fewer pack-years, a lower prevalence of respiratory symptoms except 
for dyspnea, and lower FVC and higher FEV
1
. The probability of known heart disease was 
significantly lower in the LLN+/FR+ group compared with those with preserved lung function 
(LLN−/FR−) (adjusted odds ratio 0.62, 95% CI: 0.43–0.90) but this was not seen in the LLN−/
FR+ group (adjusted odds ratio 0.90, 95% CI: 0.63–1.29).
Conclusion: In symptomatic individuals, defining airflow obstruction by FR instead of LLN 
identifies a significant number of individuals who have less respiratory and more cardiac 
clinical characteristics.
Keywords: lower limit of normal, diagnostic criteria, primary care
Introduction
COPD is the third leading cause of premature mortality and the fifth leading cause of 
disability adjusted life years globally.1 Huge efforts have been made to improve the 
diagnosis of COPD in primary care. However, the definition of COPD remains an 
unresolved issue with controversy remaining about the criteria for defining airflow 
obstruction. The Global Initiative for Obstructive Lung Disease (GOLD) and the 
National Institute for Health and Care Excellence (NICE) in the UK recommend the 
use of a fixed ratio (FR) of forced expiratory volume in 1 s (FEV
1
) to forced vital 
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capacity (FVC) of 0.7 as the diagnostic threshold for air-
flow obstruction.2,3 However, this criterion does not take into 
consideration that FEV
1
/FVC declines with age and differs 
between the sexes and by ethnicity.4
A number of epidemiological analyses suggest that using 
the FR criterion misclassifies a significant proportion of 
healthy older men as having airflow obstruction and under-
diagnoses younger females.5 There is also particular concern 
that using this criterion misclassifies patients with breathless-
ness due to cardiovascular disease6 who then may miss out on 
necessary treatment, while receiving inappropriate medication 
and potentially adverse outcomes.7,8 The European Respira-
tory Society (ERS) and American Thoracic Society (ATS) 
recommend using a more statistics-based definition of airflow 
obstruction derived from population-based reference values.9 
This defines individuals with an FEV
1
/FVC below the lower 
limit of normal (LLN; below the fifth percentile adjusted 
for age, sex, height, and ethnic group), as having airflow 
obstruction.10 There is increasing evidence that this approach 
correlates better with clinical outcomes than the FR.6
With increasing emphasis on actively case finding undi-
agnosed COPD,2 there is potential for large numbers of new 
cases to be diagnosed.11 In this context, it is important that 
misdiagnosis is avoided and those more likely to benefit are 
identified. A large randomized controlled trial was conducted 
in the West Midlands, UK, evaluating the effectiveness and 
cost-effectiveness of COPD case finding in primary care.12,13 
This trial offered spirometry to subjects with respiratory symp-
toms aged 40 years. The objective of the present study was 
to compare the clinical characteristics of symptomatic patients 
in primary care with case-found COPD diagnosed when using 
the FR criterion with those identified when using the LLN.
Methods
study design
This is a post hoc cross-sectional analysis of data from 
TargetCOPD, which was a cluster-randomized controlled 
trial based in primary care that compared 2 approaches to 
COPD case finding against usual care. Full details of the trial 
have been previously described.12 In the case-finding arm, 
patients aged 40–79 years with no prior diagnosis of COPD 
were eligible. Participants were provided with respiratory 
questionnaires that ascertained information on demographic 
characteristics, symptoms, smoking history, and self-reported 
comorbidities. Responders reporting respiratory symptoms 
(either chronic cough/phlegm for 3 months for at least 
2 years, or wheeze in the last 12 months, or Medical Research 
Council [MRC] grade 2 dyspnea or worse) were invited for a 
spirometry assessment. The current analysis used data from 
subjects recruited in practices randomized to the case-finding 
arm of the trial who attended a spirometry assessment.
setting
The case-finding arm of TargetCOPD included 27 general 
practices from the West Midlands, UK, with participation 
from August 2012 to June 2014.
Participants
All subjects included in this analysis had participated in the 
case-finding arm of TargetCOPD, had reported at least 1 
respiratory symptom (as detailed previously), had provided 
written informed consent, and had attended a spirometry 
assessment. Subjects were identified through electronic 
searches of general practice registers. Initially, only ever 
smokers were eligible, although due to difficulties with accu-
rate identification from primary care health records, never 
smokers were also included. General practitioners could 
exclude patients at their discretion if, for example, they had 
dementia, a recent bereavement, or terminal diagnosis.
spirometry assessment
Spirometry was performed by research assistants who had 
been trained using a short modified program modeled on the 
Association of Respiratory Technologists and Physiologists 
spirometry course at the lung function laboratory at Queen 
Elizabeth Hospital Birmingham. The research assistants also 
received additional training every 6 months during the course 
of the study. Post-bronchodilator spirometry was performed 
according to ATS and ERS guidelines using EasyOne ultra-
sonic flow head spirometers (ndd Medical Technologies, 
Zurich) with bespoke software (developed by MRM). Four 
100 µg doses of salbutamol were administered via a Volu-
matic spacer 20 min prior to performing spirometry. Every 
spirometry trace was over-read and quality assured by a lung 
function specialist (MRM) and spirometers underwent daily 
calibration checks. Patients’ height was measured to the 
nearest centimeter using a portable stadiometer (or estimated 
from arm-span where necessary).
Diagnosis of COPD
COPD was defined as having airflow obstruction according 
to 2 separate criteria, among those with respiratory symptoms 
(as described previously):
1. Post-bronchodilator FEV
1
/FVCLLN, defined as a 
z-score for FEV
1
/FVC below the fifth percentile from 
the GLI 2012 lung function reference equations (“LLN 
criterion”).10
2. Post-bronchodilator FEV
1
/FVC0.7 (“FR criterion”).
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
7.
18
8.
10
8.
97
 o
n 
12
-O
ct
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2018:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1981
COPD diagnosed by the fixed ratio and lower limit of normal
Data collected
Data from self-reported questionnaires were available on 
sociodemographic characteristics (age, sex, ethnic group, 
and socioeconomic status), smoking status (including pack-
years), self-reported comorbidities (hypertension, heart dis-
ease, heart failure, diabetes, stroke, lung cancer, tuberculosis, 
and depression), respiratory symptoms (cough, phlegm, 
wheeze, dyspnea, and rhinorrhea), COPD assessment test 
(CAT) scores, and overall quality of life (EQ-5D).
statistical methods
The sociodemographic and clinical characteristics of subjects 
were summarized separately according to the following 
4 diagnostic groupings:
1. Normal spirometry according to both LLN and FR criteria 
(LLN−/FR−).
2. Airflow obstruction according to both criteria (LLN+/
FR+).
3. Airflow obstruction according to the FR but not LLN 
(LLN−/FR+).
4. Airflow obstruction according to LLN but not the FR 
(LLN+/FR−).
Continuous variables were summarized as means and 
SDs and categorical variables as percentages. The FEV
1
, 
FVC, and FEV
1
/FVC ratio were summarized as z-scores 
using GLI 2012 equations.10 Clinical characteristics were 
compared across groups using Kruskal–Wallis H-tests for 
continuous variables (as they had skewed distributions), 
and chi-squared tests for categorical variables. The main 
comparisons were bivariate analyses between the LLN+/
FR+ and LLN−/FR+ groups, and between the LLN+/FR+ 
and LLN−/FR− groups, comparing the prevalence of each 
characteristic. The p-value thresholds for statistical signifi-
cance were adjusted for multiple testing using the Bonferroni 
correction.14
Since previous literature has suggested that use of the 
FR tends to include more patients with cardiovascular dis-
ease than the LLN criteria,6 we tested this hypothesis in our 
data using a logistic regression model with self-reported 
cardiovascular disease (composite outcome of self-reported 
heart disease and/or heart failure) as the outcome, and LLN/
FR status as an independent variable with models derived 
adjusting for age, sex, smoking status, self-reported diabetes 
mellitus, and hypertension.
ethical approval
Research governance and ethics approval for TargetCOPD 
was provided by the Solihull Research Ethics Committee 
(Ref: 11/WM/0403).
Results
The case-finding arm of TargetCOPD had 32,811 eligible 
participants. Questionnaires were given to 22,116 and 7,778 
responded, of whom, 4,355 (56%) reported respiratory symp-
toms. From those with symptoms, 3,721 were invited for a 
spirometry assessment and 2,607 (70%) attended and were 
included in the current analysis (Figure 1).
The mean age of the included 2,607 participants was 
60.4 years, 52.8% were male, and 29.8% were current 
smokers. The demographic characteristics, smoking status, 
BMI, and spirometry results are summarized in Table 1, strat-
ified by diagnostic criteria for airflow obstruction. There were 
851 (32.6%) individuals with airflow obstruction according to 
the FR, of whom, 527 (20.2%) met the LLN criterion (LLN+/
FR+). A total of 324 (12.4%) had airflow obstruction only by 
the FR but not by the LLN (LLN−/FR+), and 1,753 (67.2%) 
did not meet the criteria for airflow obstruction by either 
criteria (Figure 1). Not included in Table 1 are 3 individuals 
with airflow obstruction by the LLN but not identified by 
the FR criterion. They were all younger females (mean age 
46.1 years), with a mean pack-year history of 2.9, BMI of 
31.3, and FEV
1
/FVC z-score of −1.73.
Compared with the LLN+/FR+ group, patients in the 
LLN−/FR+ group were older and had better lung function 
(higher FEV
1
 and FEV
1
/FVC z-scores). A higher proportion 
was male, although this difference was not statistically sig-
nificant. However, smoking pack-years was similar between 
the LLN+/FR+ and LLN−/FR+ groups, both of which were 
significantly higher than for subjects with preserved lung 
function (LLN−/FR−). Compared with the LLN+/FR+ group, 
???????????????
??????????????????
?????????????
????????????
?????????????
Figure 1 number of participants in the 4 diagnostic groups.
Note: For clarity, the dimensions are not exactly to scale.
Abbreviations: FR, fixed ratio (FEV1/FVC0.7); LLN, lower limit of normal (FEV1/
FVC5th percentile); FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
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subjects in the LLN−/FR− group were younger, and had a 
higher BMI, fewer pack-years, and worse zFVC but higher 
zFEV
1
 and zFEV
1
/zFVC.
Table 2 summarizes the symptoms, self-reported comor-
bidities, and quality of life for participants, stratified by 
diagnostic group. Symptoms of cough, sputum, and wheeze 
were all more prevalent in the LLN+/FR+ group compared 
with the LLN−/FR+ and the LLN−/FR− groups. CAT scores 
were 2 points higher (equivalent to the minimum clinically 
significant difference15) in the LLN+/FR+ than the LLN−/
FR+ group, although there was a substantial amount of miss-
ing data (12.8%) for this variable. However, there were no 
significant differences in overall quality of life (as measured 
by EQ-5D). In contrast to the LLN+/FR+ group, the overall 
symptom burden in the LLN−/FR+ group was similar to 
the unobstructed group (LLN−/FR−), except for a slightly 
higher prevalence of wheeze. The 3 patients with airflow 
obstruction by the LLN but not by the FR criterion were 
significantly more symptomatic than the other groups with 
a mean CAT score of 17.
The prevalence of heart disease was significantly higher 
in the LLN−/FR+ group compared with the LLN+/FR+ 
group (14.2% versus 6.9%, p0.001) but the LLN−/FR+ 
group also had a significantly lower prevalence of depression 
(Table 2; Figure 2). The prevalence of asthma was signifi-
cantly higher in the LLN+/FR+ group compared with the 
LLN−/FR− group (30.9% versus 18.4%, p0.001). While 
this was also observed when comparing the LLN+/FR+ with 
the LLN−/FR+ group, this difference did not reach statistical 
significance. After adjusting for age and sex, the LLN+/FR+ 
group had a significantly lower probability of having heart 
disease compared with the LLN−/FR− group (odds ratio 0.57, 
95% CI: 0.40–0.81) but no significant difference was found 
for the LLN−/FR+ group (Table 3). The same associations 
Table 1 Demographic characteristics and spirometry results stratified by diagnostic criteria
Participant 
characteristics
LLN+/FR+ LLN−/FR+ LLN−/FR−
N (%)a p-valueψ N (%)a p-value$ N (%)a
subjects 527 324 1,753
Male 292 (55.4) 0.056 196 (60.5) 0.145 889 (50.7)
Age (years)
Mean (SD) 61.5 (9.8) 0.0001* 68.6 (7.2) 0.0001* 58.6 (10.5)
40–49 81 (15.4) 3 (0.9) 436 (24.9)
50–59 139 (26.4) 41 (12.7) 523 (29.8)
60–69 185 (35.1) 130 (40.1) 484 (27.6)
70–79 122 (23.1) 150 (46.3) 310 (17.7)
ethnicity
White 472 (89.7) 300 (92.6) 1,477 (84.4)
afro-Caribbean 10 (1.9) 6 (1.9) 76 (4.3)
asian 26 (4.9) 7 (2.2) 127 (7.3)
Mixed 5 (1.0) 0 (0.0) 25 (1.4)
Other 14 (2.7) 11 (3.4) 49 (2.8)
BMI (kg/m3)
Mean (SD) 29.1 (6.5) 0.0001* 29.9 (6.0) 0.03 30.5 (6.4)
18.5 6 (1.1) 2 (0.6) 5 (0.3)
18.5–24.9 127 (24.2) 63 (19.5) 280 (16.1)
25.0–29.9 193 (36.8) 121 (37.5) 649 (37.3)
30 201 (38.4) 138 (42.7) 819 (47.0)
lung function
FEV1 L (SD) 2.19 (0.68) 2.43 (0.64) 2.81 (0.74)
zFEV1 (SD) −1.59 (0.99) 0.0001* −0.69 (0.89) 0.0001* −0.32 (0.98)
FVC L (SD) 3.73 (1.03) 3.60 (0.94) 3.62 (0.95)
zFVC (SD) 0.01 (1.11) 0.0001* 0.07 (1.04) 0.58 −0.26 (1.00)
FEV1/FVC (SD) 0.59 (0.08) 0.67 (0.02) 0.78 (0.05)
zFEV1/FVC −2.48 (0.68) 0.0001* −1.28 (0.26) 0.0001* −0.16 (0.72)
Pack years
Mean (SD) 25.2 (21.4) 0.0001* 25.3 (27.6) 0.0001* 16.9 (20.1)
smoking status
never 71 (13.5) 53 (16.6) 422 (24.4)
Former 212 (40.5) 207 (64.9) 843 (48.6)
Current 241 (46.0) 59 (18.5) 468 (27.0)
Notes: z prefix denotes the z-score for the lung function index. aUnless otherwise specified. The results for LLN−/Fr+ were compared with lln+/Fr+ ($) and results 
for lln+/Fr+ were compared with lln−/Fr− (ψ) using Pearson Chi-square test for sex differences and Kruskal–Wallis tests for the other indices. *p-values 0.001 are 
significant in accordance with Bonferroni correction for multiple comparisons.
Abbreviations: FEV1, forced expiratory volume in 1s; FR, fixed ratio; FVC, forced vital capacity; LLN, lower limit of normal; BMI, body mass index.
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were found after adjusting for smoking status, self-reported 
diabetes mellitus, and hypertension.
Discussion
Main findings
Within a primary care population of previously undiagnosed 
adults with chronic respiratory symptoms, using the FR to 
define airflow obstruction resulted in a higher proportion 
being classified as having COPD, compared with using the 
LLN criterion (32.6% versus 20.2%, respectively). Those 
diagnosed with COPD by the FR but not by LLN were 
older, and had better lung function, lower symptom burden, 
a higher prevalence of self-reported cardiovascular disease, 
and a lower prevalence of depression, compared with those 
classified as having COPD by both criteria. Those diagnosed 
Table 2 Self-reported symptoms, comorbidities and quality of life, stratified by diagnostic criteria
LLN+/FR+ LLN−/FR+ LLN−/FR−
N (%)a p-valueψ N (%)a p-value$ N (%)a
subjects 527 324 1,753
symptoms
Wheeze 420 (80.5) 0.001* 221 (69.3) 0.001* 1,133 (65.6)
sputum 314 (60.9) 0.001* 141 (44.8) 0.001* 843 (49.3)
Dyspnea 399 (75.7) 0.063 231 (71.3) 0.145 1,255 (71.6)
Cough 309 (59.7) 0.001* 138 (41.4) 0.001* 743 (43.1)
Chr cough 152 (28.8) 0.002 67 (20.7) 0.008 373 (21.3)
Chr sputum 118 (22.4) 0.001* 49 (15.6) 0.145 276 (15.7)
Comorbidities
heart disease 36 (6.9) 0.109 46 (14.2) 0.001* 159 (9.1)
heart failure 10 (1.9) 0.086 13 (4.0) 0.068 59 (3.4)
hypertension 205 (39.2) 0.697 161 (49.7) 0.003 699 (40.1)
Diabetes 59 (11.3) 0.022 58 (17.9) 0.007 266 (15.3)
stroke 19 (3.6) 0.129 20 (6.2) 0.088 42 (2.4)
Depression 114 (21.8) 0.776 36 (11.1) 0.001* 390 (22.4)
asthma 163 (30.9) 0.001* 74 (22.8) 0.009 322 (18.4)
mMrC dyspnoea
Median (IQR) 1 (1–2) 0.002 1 (0–2) 0.092 1 (0–2)
0 120 (24.0) 91 (29.1) 486 (28.9)
1 173 (34.5) 111 (35.5) 628 (37.3)
2 87 (17.4) 39 (12.5) 227 (13.5)
3 74 (14.8) 46 (14.7) 219 (13.0)
4 47 (9.4) 26 (8.3) 122 (7.3)
CaT score
Median (IQR) 12 (7–19) 0.001* 10 (6–16) 0.001* 11 (6–16)
0–10 205 (43.9) 149 (53.6) 756 (49.5)
11–20 174 (37.3) 91 (32.7) 555 (36.4)
21–30 71 (15.2) 32 (11.5) 187 (12.3)
31–40 17 (3.6) 6 (2.2) 28 (1.8)
EQ-5D
Median (IQR) 0.80 (0.68–1.0) 0.80 0.77 (0.64–0.91) 0.013 0.80 (0.68–1.0)
Notes: aUnless otherwise specified. Results for LLN−/Fr+ were compared with lln+/Fr+ ($) and results for LLN+/Fr+ were compared with lln−/Fr− (ψ) using Pearson 
chi-square tests. *p-values 0.001 are statistically significant in accordance with Bonferroni correction for multiple comparisons.
Abbreviations: CAT, COPD Assessment Test; Chr, chronic; EQ-5D, EuroQol-5D (measure of quality of life); FR, fixed ratio; IQR, interquartile range; LLN, lower limit of 
normal; mMRC, modified Medical Research Council score.
Figure 2 Prevalence of cardiovascular disease by diagnostic group.
Abbreviations: FR, fixed ratio (FEV1/FVC0.7); LLN, lower limit of normal (FEV1/
FVC5th percentile); FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
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with COPD by LLN were also significantly more likely to 
have a past history of asthma than those without airflow 
obstruction. In addition, using the LLN classified a small 
number of younger, very symptomatic females as having 
COPD that the FR excluded. Finally, symptomatic individu-
als with preserved lung function appeared to have a higher 
probability of having heart disease and a lower FVC than 
those with airflow limitation by LLN.
relationship to other studies
The potential for over-diagnosis of COPD using the FR has 
been previously demonstrated. A population prevalence 
study of COPD in England and Wales for ages 40–95 years 
found FR-defined airflow obstruction in 22% of subjects but 
in only 13% when using the LLN criterion.16 Our findings 
also agreed with an analysis of the CanCOLD study, a large 
prospective population-based cohort study of COPD in 
Canada.6 This concluded that use of the FR for diagnosing 
airflow obstruction could lead to the misdiagnosis of older 
males with a history of cardiovascular disease. The authors 
proposed using an FEV
1
80% predicted as an additional cri-
terion for restricting the diagnosis to patients with a clinically 
more significant degree of airflow obstruction. Indeed, this 
approach was previously recommended by NICE.3 However, 
this approach still does not adequately account for variation 
in lung function by age, sex, and height, and therefore, can 
still lead to misclassification.17 Using FEV
1
LLN as an 
alternative criterion would avoid this bias.
The Austria Burden of Obstructive Lung Disease study 
similarly evaluated whether the diagnostic criterion for air-
flow obstruction was associated with the prevalence of heart 
disease.18 Among 1,258 screened adults aged 40 years (with 
and without symptoms), 27% of LLN−/FR+ cases had self-
reported heart disease compared to 15% of LLN+ cases.
It has been suggested that the LLN−/FR+ cases have 
COPD with heart disease as a comorbidity, which may 
account for their poorer prognosis in terms of higher risk 
of hospitalization and premature mortality.19 However, the 
observation that these individuals are older with a higher 
comorbidity burden, and yet have better lung function,20 
suggests that heart disease may be their primary diagnosis. 
COPD is characterized by gradual and inexorable decline 
in lung function with increasing dyspnea and those with 
relatively good lung function would not be expected to have 
a high rate of early mortality from COPD.
It is well recognized that the FR criterion will not only 
over-diagnose airflow obstruction in the older population 
but also miss the diagnosis in younger females.5,6,21,22 In the 
current study, the 3 highly symptomatic females who were 
misclassified as having no airflow obstruction using the FR 
potentially have a lot to gain from clinical intervention.
A recent study of patients with COPD using a FR defini-
tion of airflow obstruction23 found marked differences in how 
subjects were classified by the 2011 GOLD symptom-related 
classification (A, B, C, and D)24 depending on whether the 
modified MRC (mMRC) or CAT scores were used to assess 
subjects. Use of the CAT score tended to reduce the preva-
lence of cardiac comorbidities in the 2 more severe groupings. 
The mMRC rating of dyspnea is not specific to respiratory 
disease whereas the CAT score measures disease-specific 
quality of life and includes 7 other domains, some being more 
specific to COPD. This lends weight to the possibility that a 
combination of mMRC dyspnea and FEV
1
/FVC0.7 may 
over-represent primary cardiac disease rather than COPD. 
Related to this, our study found that the prevalence of dysp-
nea was similar between individuals diagnosed with COPD 
by either diagnostic criterion whereas cough and sputum 
were less prevalent in the LLN−/FR+ group.
Guder et al prospectively studied 405 individuals 
aged 65 years with a GP diagnosis of COPD.25 They 
examined FR and LLN criteria for airflow obstruction and 
compared this with a COPD diagnosis by an expert panel 
that had access to clinical information, radiology, and lung 
Table 3 logistic regression model evaluating the association 
between risk of heart disease and presence of airflow limitation 
by different criteria
Model 1 
(n=2,589)
Model 2 
(n=2,561)
Model 3 
(n=2,559)
OR (95% CI) OR (95% CI) OR (95% CI)
sex
Female 1.00 1.00 1.00
Male 1.98 (1.51–2.59) 2.03 (1.54–2.67) 1.92 (1.46–2.54)
age 1.08 (1.06–1.10) 1.07 (1.06–1.09) 1.07 (1.05–1.09)
Diagnostic group
lln−/Fr− 1.00 1.00 1.00
lln−/Fr+ 0.85 (0.60–1.21) 0.87 (0.61–1.23) 0.90 (0.63–1.29)
lln+/Fr+ 0.57 (0.40–0.81) 0.59 (0.41–0.85) 0.62 (0.43–0.90)
smoking status
never 1.00 1.00
Former 0.99 (0.72–1.38) 0.98 (0.71–1.37)
Current 0.87 (0.57–1.32) 0.89 (0.58–1.36)
Co-morbidities
Diabetes 
mellitus
1.71 (1.26–2.32)
hypertension 1.73 (1.32–2.27)
Notes: Heart disease was defined by the presence of self-reported heart disease 
(n=241) or heart failure (n=82) or both (n=35). The lln−/Fr− group was the 
reference group with Model 1 adjusted for sex and age, Model 2 also adjusted for 
smoking status, and Model 3 also adjusted for diabetes mellitus and hypertension 
(n=2,559 with complete data).
Abbreviations: FR, fixed ratio (FEV1/FVC0.7); LLN, lower limit of normal (FEV1/
FVC5th percentile); OR, odds ratio; FEV1, forced expiratory volume in 1 s; FVC, 
forced vital capacity.
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COPD diagnosed by the fixed ratio and lower limit of normal
function. Both criteria misclassified patients when using the 
expert panel diagnosis as the reference standard. The FR 
criterion was associated with more false positive diagnoses 
and the LLN criterion with more false negatives. Expert 
panel diagnosis was a better predictor of exacerbations, 
hospitalizations, and mortality, than either the FR or LLN 
criteria, highlighting the importance of a holistic assessment 
in addition to lung function measurement for making an 
accurate diagnosis and predicting prognosis.
strengths and limitations
Our study had a large sample of symptomatic subjects 
recruited from primary care who are likely to be representa-
tive of those who would be targeted for COPD case finding. 
The study employed post-bronchodilator spirometry with 
rigorous quality assurance and collected a broad range of data 
on symptoms, comorbidities, and health-related quality of 
life, and accounted for multiple statistical comparisons.
Comorbidities were self-reported and not based on health 
records or objective measures. We also did not account for 
potential undiagnosed comorbidities. Current and former 
smokers appeared to have a lower risk of self-reported 
cardiovascular disease than never smokers, although this 
association was not statistically significant. The reason for 
this is unclear but may be because cardiovascular disease 
was self-reported, which would not account for undiagnosed 
cardiovascular disease.
There was also a significant amount of missing data for 
the CAT (12.8% missing) and MRC dyspnea (4.1% miss-
ing) scores, and no data on objective measures of exercise 
tolerance, lung imaging, gas transfer, or cardiac function 
were collected. Finally, only 35% of all eligible participants 
responded to the respiratory questionnaire and the findings 
are therefore potentially prone to responder bias.
Implications for practice, policy, and 
research
Use of the FR for defining airflow obstruction may lead to 
the inclusion of a significant number of older patients with 
a history of cardiovascular disease as having COPD. This 
could lead to symptoms related to cardiovascular disease 
being falsely attributed to airflow obstruction, resulting in 
an inappropriate management strategy. It is particularly 
important that symptomatic patients with an FEV
1
/FVC 
above the LLN (irrespective of whether the FEV
1
/FVC is 
0.7) are diagnostically assessed for cardiovascular causes 
of their symptoms and exacerbations. Cardiovascular mor-
bidity and mortality are higher in people with COPD than 
they are in the general population and cardiovascular disease 
is a more common cause of death among these individuals 
than COPD itself.26 Furthermore, the early mortality in those 
with an FEV
1
/FVC0.7 and with mild reduction in FEV
1
 has 
been found to be unexpectedly high due to cardiac disease.20 
It will be important to investigate whether cardiovascular 
disease is predominantly responsible for the symptom bur-
den experienced by these patients. This could include more 
detailed investigations for cardiovascular disease, including 
echocardiography.
Further research is also needed to understand the clinical 
implications and long-term outcomes of pursuing standard 
treatment for COPD in the LLN−/FR+ group. The burden 
of respiratory symptoms was generally lower in this group 
compared with those with airflow obstruction by LLN. This 
may potentially explain the difference in prevalence of 
depression, since these physical symptoms may contribute 
to poor mental health. However, this requires further inves-
tigation. Further investigation is also needed to understand 
the significantly high burden of self-reported asthma seen 
in those with airflow limitation by LLN.
The growing body of evidence that using the FR has 
the potential to over-diagnose COPD in older people with 
cardiovascular disease and underdiagnose younger females 
should be more fully acknowledged in clinical guidelines, 
with a recommendation to use the LLN criterion to help 
differentiate patients with COPD from those with a poten-
tial cardiovascular cause for breathlessness. This will be 
particularly important in the context of systematic case 
finding, where there is a significant risk of misdiagnosing 
large numbers of people.
Conclusion
Use of the FR for defining airflow obstruction may lead 
to the inclusion of a significant number of older people 
with breathlessness as having COPD, who may, in fact, 
have age-related changes in lung function in the presence 
of cardiovascular disease as the cause for their symptoms. 
Further research is needed to assess the long-term outcomes 
and clinical implications of using the FR versus the LLN for 
diagnosing COPD and characterize cardiovascular health in 
symptomatic subjects with lung function that is within the 
normal population reference range.
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